The pentose phosphate pathway and cancer

Trends in Biochemical Sciences

Volumn 39, Issue 8, 2014, Pages 347-354

  Patra, Krushna C ^a   Hay, Nissim ^b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 AMINONICOTINAMIDE; 6 PHOSPHOGLUCONOLACTONASE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; DOXORUBICIN; ESTERASE; FLUOROURACIL; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; PRASTERONE; PROTEIN P53; RAS PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RIBULOSE PHOSPHATE EPIMERASE; RIBULOSE PHOSPHATE ISOMERASE; TRANSALDOLASE; TRANSCRIPTION FACTOR NRF2; TRANSKETOLASE; UNCLASSIFIED DRUG;

CANCER CELL; CARCINOGENICITY; CATALYSIS; CELL METABOLISM; CELL SURVIVAL; DRUG CYTOTOXICITY; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG SENSITIZATION; ENZYME ACTIVITY; GENE DELETION; GENE MUTATION; GENE SILENCING; GLIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CANCER; MELANOMA; METASTASIS; NEOPLASM; NONHUMAN; ONCOGENE RAS; OXIDATIVE STRESS; PENTOSE PHOSPHATE CYCLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; ANIMAL; GLYCOLYSIS; METABOLISM; PATHOLOGY;

ANIMALS; GLYCOLYSIS; HUMANS; NEOPLASMS; OXIDATIVE STRESS; PENTOSE PHOSPHATE PATHWAY;

EID: 84904969433     PISSN: 09680004     EISSN: 13624326     Source Type: Journal    
DOI: 10.1016/j.tibs.2014.06.005     Document Type: Review

References (76)

1. Cordes W. Experiences with plasmochin in malaria. 15th Annual Report 1926, 66-71.
2. Alving A.S., et al. Enzymatic deficiency in primaquine-sensitive erythrocytes. Science 1956, 124:484-485.
3. Horecker B.L. The pentose phosphate pathway. J. Biol. Chem. 2002, 277:47965-47971.
4. Kruger N.J., von Schaewen A. The oxidative pentose phosphate pathway: structure and organisation. Curr. Opin. Plant Biol. 2003, 6:236-246.
5. Riganti C., et al. The pentose phosphate pathway: an antioxidant defense and a crossroad in tumor cell fate. Free Radic. Biol. Med. 2012, 53:421-436.
6. Eggleston L.V., Krebs H.A. Regulation of the pentose phosphate cycle. Biochem. J. 1974, 138:425-435.
7. Rais B., et al. Oxythiamine and dehydroepiandrosterone induce a G1 phase cycle arrest in Ehrlich's tumor cells through inhibition of the pentose cycle. FEBS Lett. 1999, 456:113-118.
8. Boros L.G., et al. Inhibition of the oxidative and nonoxidative pentose phosphate pathways by somatostatin: a possible mechanism of antitumor action. Med. Hypotheses 1998, 50:501-506.
9. Boros L.G., et al. Nonoxidative pentose phosphate pathways and their direct role in ribose synthesis in tumors: is cancer a disease of cellular glucose metabolism?. Med. Hypotheses 1998, 50:55-59.
10. Cohen P., Rosemeyer M.A. Subunit interactions of glucose-6-phosphate dehydrogenase from human erythrocytes. Eur. J. Biochem. 1969, 8:8-15.
11. Hilf R., et al. Multiple molecular forms of glucose-6-phosphate dehydrogenase in normal, preneoplastic, and neoplastic mammary tissues of mice. Cancer Res. 1975, 35:2109-2116.
12. Okano K., et al. Histochemical comparison of oxidative enzymes in adrenal glands of mammals. Histochemie 1965, 4:494-501.
13. Park J., et al. Overexpression of glucose-6-phosphate dehydrogenase is associated with lipid dysregulation and insulin resistance in obesity. Mol. Cell. Biol. 2005, 25:5146-5157.
14. Rudack D., et al. Rat liver glucose 6-phosphate dehydrogenase. Regulation by carbohydrate diet and insulin. J. Biol. Chem. 1971, 246:1249-1254.
15. Jonas S.K., et al. Increased activity of 6-phosphogluconate dehydrogenase and glucose-6-phosphate dehydrogenase in purified cell suspensions and single cells from the uterine cervix in cervical intraepithelial neoplasia. Br. J. Cancer 1992, 66:185-191.
16. + molecule and provides insights into enzyme deficiency. Structure 2000, 8:293-303.
17. Ayala A., et al. The role of NADPH in the regulation of glucose-6-phosphate and 6-phosphogluconate dehydrogenases in rat adipose tissue. Mol. Cell. Biochem. 1991, 105:1-5.
18. Stanton R.C., et al. Rapid release of bound glucose-6-phosphate dehydrogenase by growth factors. Correlation with increased enzymatic activity. J. Biol. Chem. 1991, 266:12442-12448.
19. Tian W.N., et al. Signal transduction proteins that associate with the platelet-derived growth factor (PDGF) receptor mediate the PDGF-induced release of glucose-6-phosphate dehydrogenase from permeabilized cells. J. Biol. Chem. 1994, 269:14798-14805.
20. Pan S., et al. Glucose 6-phosphate dehydrogenase is regulated through c-Src-mediated tyrosine phosphorylation in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2009, 29:895-901.
21. Toniolo D., et al. Expression of the G6PD locus on the human X chromosome is associated with demethylation of three CpG islands within 100kb of DNA. EMBO J. 1988, 7:401-406.
22. Zhang Z., et al. High glucose inhibits glucose-6-phosphate dehydrogenase via cAMP in aortic endothelial cells. J. Biol. Chem. 2000, 275:40042-40047.
23. Xu Y., et al. Diabetes causes inhibition of glucose-6-phosphate dehydrogenase via activation of PKA, which contributes to oxidative stress in rat kidney cortex. Am. J. Physiol. Renal Physiol. 2005, 289:F1040-F1047.
24. Leopold J.A., et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat. Med. 2007, 13:189-197.
25. Brodie A.F., Lipmann F. Identification of a gluconolactonase. J. Biol. Chem. 1955, 212:677-685.
26. Beutler E., et al. 6-Phosphogluconolactonase deficiency, a hereditary erythrocyte enzyme deficiency: possible interaction with glucose-6-phosphate dehydrogenase deficiency. Proc. Natl. Acad. Sci. U.S.A. 1985, 82:3876-3878.
27. Sukhatme V.P., Chan B. Glycolytic cancer cells lacking 6-phosphogluconate dehydrogenase metabolize glucose to induce senescence. FEBS Lett. 2012, 586:2389-2395.
28. Nishimura M., Uyeda K. Purification and characterization of a novel xylulose-5-phosphate-activated protein phosphatase catalyzing dephosphorylation of fructose-6-phosphate, 2-kinase:fructose-2,6-bisphosphatase. J. Biol. Chem. 1995, 270:26341-26346.
29. Ying H., et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 2012, 149:656-670.
30. Lindqvist Y., et al. Three-dimensional structure of transketolase, a thiamine diphosphate dependent enzyme, at 2.5Å resolution. EMBO J. 1992, 11:2373-2379.
31. Boros L.G., et al. Oxythiamine and dehydroepiandrosterone inhibit the nonoxidative synthesis of ribose and tumor cell proliferation. Cancer Res. 1997, 57:4242-4248.
32. Liu H., et al. Fructose induces transketolase flux to promote pancreatic cancer growth. Cancer Res. 2010, 70:6368-6376.
33. Coy J.F., et al. Mutations in the transketolase-like gene TKTL1: clinical implications for neurodegenerative diseases, diabetes and cancer. Clin. Lab. 2005, 51:257-273.
34. Langbein S., et al. Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted. Br. J. Cancer 2006, 94:578-585.
35. Meshalkina L.E., et al. Is transketolase-like protein, TKTL1, transketolase?. Biochim. Biophys. Acta 2013, 1832:387-390.
36. Heinrich P.C., et al. Behavior of transaldolase (EC 2.2.1.2) and transketolase (EC 2.2.1.1). Activities in normal, neoplastic, differentiating, and regenerating liver. Cancer Res. 1976, 36:3189-3197.
37. Hanczko R., et al. Prevention of hepatocarcinogenesis and increased susceptibility to acetaminophen-induced liver failure in transaldolase-deficient mice by N-acetylcysteine. J. Clin. Invest. 2009, 119:1546-1557.
38. Schwartzenberg-Bar-Yoseph F., et al. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res. 2004, 64:2627-2633.
39. Hitosugi T., et al. Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer Cell 2012, 22:585-600.
40. Kondoh H., et al. Glycolytic enzymes can modulate cellular life span. Cancer Res. 2005, 65:177-185.
41. Bensaad K., et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006, 126:107-120.
42. Cheung E.C., et al. Mitochondrial localization of TIGAR under hypoxia stimulates HK2 and lowers ROS and cell death. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:20491-20496.
43. Lowman X.H., et al. The proapoptotic function of Noxa in human leukemia cells is regulated by the kinase Cdk5 and by glucose. Mol. Cell 2010, 40:823-833.
44. Cosentino C., et al. ATM activates the pentose phosphate pathway promoting anti-oxidant defence and DNA repair. EMBO J. 2011, 30:546-555.
45. Jiang P., et al. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat. Cell Biol. 2011, 13:310-316.
46. Du W., et al. TAp73 enhances the pentose phosphate pathway and supports cell proliferation. Nat. Cell Biol. 2013, 15:991-1000.
47. Patra K.C., et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell 2013, 24:213-228.
48. Duvel K., et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 2010, 39:171-183.
49. Quinn W.J., Birnbaum M.J. Distinct mTORC1 pathways for transcription and cleavage of SREBP-1c. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:15974-15975.
50. Taguchi K., et al. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells 2011, 16:123-140.
51. Mitsuishi Y., et al. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 2012, 22:66-79.
52. DeNicola G.M., et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2011, 475:106-109.
53. Mitsuishi Y., et al. The Keap1-Nrf2 system in cancers: stress response and anabolic metabolism. Front. Oncol. 2012, 2:200.
54. Jaramillo M.C., Zhang D.D. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev. 2013, 27:2179-2191.
55. Muscarella L.A., et al. Regulation of KEAP1 expression by promoter methylation in malignant gliomas and association with patient's outcome. Epigenetics 2011, 6:317-325.
56. Muscarella L.A., et al. Frequent epigenetics inactivation of KEAP1 gene in non-small cell lung cancer. Epigenetics 2011, 6:710-719.
57. Nogueira V., Hay N. Molecular pathways: reactive oxygen species homeostasis in cancer cells and implications for cancer therapy. Clin. Cancer Res. 2013, 19:4309-4314.
58. Schafer Z.T., et al. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 2009, 461:109-113.
59. Jeon S.M., et al. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 2012, 485:661-665.
60. Jeon S.M., Hay N. The dark face of AMPK as an essential tumor promoter. Cell. Logist. 2012, 2:197-202.
61. Langbein S., et al. Metastasis is promoted by a bioenergetic switch: new targets for progressive renal cell cancer. Int. J. Cancer 2008, 122:2422-2428.
62. Lu X., et al. Metabolomic changes accompanying transformation and acquisition of metastatic potential in a syngeneic mouse mammary tumor model. J. Biol. Chem. 2010, 285:9317-9321.
63. Chen E.I., et al. Adaptation of energy metabolism in breast cancer brain metastases. Cancer Res. 2007, 67:1472-1486.
64. Przybytkowski E., Averill-Bates D.A. Correlation between glutathione and stimulation of the pentose phosphate cycle in situ in Chinese hamster ovary cells exposed to hydrogen peroxide. Arch. Biochem. Biophys. 1996, 325:91-98.
65. Tuttle S., et al. Glucose-6-phosphate dehydrogenase and the oxidative pentose phosphate cycle protect cells against apoptosis induced by low doses of ionizing radiation. Radiat. Res. 2000, 153:781-787.
66. Yeh G.C., et al. Adriamycin resistance in human tumor cells associated with marked alteration in the regulation of the hexose monophosphate shunt and its response to oxidant stress. Cancer Res. 1987, 47:5994-5999.
67. 31P NMR and enzymatic studies. Anticancer Res. 1993, 13:867-872.
68. Friesen C., et al. A critical role of glutathione in determining apoptosis sensitivity and resistance in leukemia cells. Cell Death Differ. 2004, 11(Suppl. 1):S73-S85.
69. Gessner T., et al. Elevated pentose cycle and glucuronyltransferase in daunorubicin-resistant P388 cells. Cancer Res. 1990, 50:3921-3927.
70. Lai G.M., et al. Contribution of glutathione and glutathione-dependent enzymes in the reversal of adriamycin resistance in colon carcinoma cell lines. Int. J. Cancer 1991, 49:688-695.
71. Shin Y.K., et al. Upregulation of glycolytic enzymes in proteins secreted from human colon cancer cells with 5-fluorouracil resistance. Electrophoresis 2009, 30:2182-2192.
72. Bachur N.R., et al. NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals. Proc. Natl. Acad. Sci. U.S.A. 1979, 76:954-957.
73. Anastasiou D., et al. Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 2011, 334:1278-1283.
74. Yi W., et al. Phosphofructokinase 1 glycosylation regulates cell growth and metabolism. Science 2012, 337:975-980.
75. Ros S., et al. Functional metabolic screen identifies 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 as an important regulator of prostate cancer cell survival. Cancer Discov. 2012, 2:328-343.
76. Clasquin M.F., et al. Riboneogenesis in yeast. Cell 2011, 145:969-980.